80 mg/day in enteric-coated capsules, one daily dose in the morning. High dose: 160 mg. Effects from 2 weeks, full at 6–10 weeks.
Meta-analysis of 5 RCTs (n=524 at 80 mg and 121 at 160 mg): HAM-A reduction of −14.1 points with 160 mg/day, −12.8 with 80 mg/day, comparable to paroxetine 20 mg (−11.3) and superior to placebo (−9.5). Effect established at 6–10 weeks.
View the study (meta-analysis) →Specific meta-analysis in subthreshold anxiety and mixed anxiety-depressive disorder (MADD): consistent improvement vs placebo with clinically relevant magnitude.
View the study (meta-analysis) →Unlike benzodiazepines and kava, it does not cause tolerance or dependence. Discontinuation without withdrawal syndrome.
View the study (RCT) →Randomized trial in mild-to-moderate depression: improvement comparable to a reference SSRI, with better tolerability. Extrapolate with caution; the main effect is on anxiety symptoms.
View the study (RCT) →Improves subjective sleep quality in people with anxiety, without causing daytime sedation or affecting sleep architecture.
View the study (RCT) →Trial in social phobia: significant reduction in LSAS at 10 weeks with 160 mg/day. An alternative to beta-blockers for specific presentations/events, although the effect is baseline, not momentary.
Preliminary data suggest a reduction in panic attack frequency. Specific double-blind RCTs are lacking.
Information, not medical advice. Scientific evidence reflects the quality of the studies.